Rome, Italy (ots) - The MASCC (Multinational Association of Supportive Care in Cancer) 2009 International Symposium opens today in Rome, Italy - Chemotherapy-induced nausea and vomiting (CINV), treatment of pain, and quality of life in survivors among the key topics of the conference "Supportive care in cancer is a field of increasing relevance for both ...
Berlin, Germany (ots) - Single dose palonosetron is effective and safe in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with aggressive non-Hodgkin's lymphomas who undergo moderately emetogenic chemotherapy. Data presented today at the European Haematology Association Congress in Berlin, Germany New data presented today at the EHA ...
Investment in line with the Government and IDA strategy for R&D Lugano, Switzerland/Dublin, Ireland (ots) - Helsinn together with the Irish Tánaiste and Minister for Enterprise, Trade and Employment Mary Coughlan TD, today announced, that Helsinn Holding S.A., a privately owned pharmaceutical company, is to establish a Centre-of-excellence in Research and ...
Lugano, Switzerland (ots) - A new release of the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology on Antiemesis recommends palonosetron as the "preferred" 5-HT3 antagonist in combination with aprepitant and dexamethasone for prevention of emesis in highly emetic risk ...
Zurich, Switzerland (ots) - A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented today at the ESMO ...
Lugano (ots) - Helsinn, the chemical pharmaceutical group based in Lugano and Biasca is pleased to announce today that it has awarded a grant for the sum of CHF 30'000 to the Institute of Research in Biomedicine (IRB) in Bellinzona, under the direction of Prof. Dr. Antonio Lanzavecchia. The grant will be used for research work performed by Prof. Markus Manz, in the ...
New gonadotrophin-releasing hormone (GnRH) receptor antagonist demonstrates rapid, long-term suppression of testosterone Saint-Prex (ots) - Ferring Pharmaceuticals announced today that it has received marketing authorisation from the European Commission, for FIRMAGON® (degarelix), a new GnRH receptor antagonist ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin® candidate PRS-050, a potent VEGF antagonist with broad ...
Lugano (ots) - Today the Swiss pharmaceutical group Helsinn announced the acquisition, of the US biopharmaceutical company, Sapphire Therapeutics Inc. with headquarters in Bridgewater, New Jersey, for an undisclosed amount. The establishment of a US-based R&D and commercial operation represents attainment of ...
Zug, Switzerland (ots) - Swiss AmVac AG establishes comprehensive collaboration with the National Health Research Institutes in Taiwan to combat H5N1. H5N1/Influenza A is a flu virus known colloquially as "avian flu". "Avian flu" first occurred in Asia, and was transmitted to humans in a number of cases. ...
Lugano, Switzerland (ots) - Helsinn is delighted to announce that its drug product manufacturing facility in Dublin, Ireland, Helsinn Birex Pharmaceuticals, has recently obtained an authorisation for Manufacture of Investigational Medicinal Products (IMP) for products for human use from the Irish Medicines Board ...
Zurich (ots) - Solianis has just finalized a test series in which patients with diabetes have worn the first configuration of the multisensor system for non-invasive Continuous Glucose Monitoring at home and at work. Results show that the system tracks glucose in these settings and that it is sensitive to hyper- ...
- Indication: The full press release can be downloaded free of charge under: http://www.presseportal.ch/de/pm/100007839 - Ecublens/Lausanne, Switzerland (ots) - - AC Immune selected as Technology Pioneer 2009 by the ...
Lugano, Switzerland (ots) - Helsinn Healthcare's Top management today announced that it has signed a partnering agreement with Zealand Pharma, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting ...
Berlin (ots) - The new compounds will provide a "full time" protection of neurons against aging and degeneration. Continuous administration technologies, which are one of the core competencies of Axxonis Pharma AG, will additionally enable the concept of 24 hours protection. This is a completely new and innovative approach in radical scavenging therapy and in ...
New data on the mechanism of action of the second generation 5-HT3 antagonist palonosetron presented today at the 33rd ESMO Congress in Stockholm, Sweden Stockholm, Sweden (ots) - New data presented today at the 33rd ESMO (European Society of Medical Oncology) Congress in Stockholm may contribute to explain the reason why palonosetron, a second generation 5-HT3 ...
Dublin, Ireland (ots) - Helsinn is pleased to announce that Helsinn Birex Pharmaceuticals, its drug facility in Dublin Ireland, has undergone a successful inspection by the US Food and Drug Administration (FDA) without any Form 483 observations. The FDA visit, which lasted 5 days, was a pre-approval inspection ...
Zug (ots) - The Swiss company AmVac AG, a biopharmaceutical company based in Zug, has announced the expansion of its Advisory Board. With the acquisition of Hartmut Retzlaff, CEO of STADA Arzneimittel AG, AmVac now has one of the most successful company managers in the German pharmaceutical industry on the Board. Hartmut Retzlaff has been head of STADA AG since 1994 ...
Lugano (ots) - Helsinn's Top Management and its U.S. partner Eisai Inc. today announced the availability in the USA of ALOXI® (palonosetron hydrochloride) injection 0.075 mg for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. The introduction of ALOXI® for PONV ...
Zug, Catania (ots) - AmVac AG, a Swiss biopharmaceutical company based in Zug, is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the first time in tobacco plants which along with AmVac AG's ...
München, Deutschland und Chicago, USA (ots) - Treatment with the trifunctional antibody catumaxomab significantly prolongs puncture-free survival in patients with malignant ascites, according to the results from a Phase II/III trial presented at the 44th American Society of Clinical Oncology (ASCO) congress. ...
Appenzell (ots) - Ergonex Pharma today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe. "The ...
Roche Professional Diagnostics
Rotkreuz, Switzerland (ots) - Roche Diagnostics announced today that the Elecsys Anti-HCV (Hepatitis C Virus) assay has received regulatory approval in Europe for the E 170 analyzer for MODULAR ANALYTICS and the e 601 module for the cobas 6000 platform. The Elecsys Anti-HCV assay is already available on the Elecsys 2010 and the cobas e 411 instruments. Hepatitis C virus (HCV) infection represents a major cause ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round. Led by new investor OrbiMed Advisors LLC, a major global fund dedicated to healthcare, ...
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, together with its partner EISAI Corporation of North America and EISAI's U.S. subsidiary, MGI Pharma, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi® (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for ...
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, today announced that it has signed a Distribution and License Agreement for Aloxi® (Palonosetron hydrochloride) and Gelclair® in Germany with Riemser Arzneimittel AG, a medium-sized pharmaceutical group engaging in research, headquartered in ...
Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...
LUGANO, Switzerland and MINNEAPOLIS, MN (ots) - Helsinn Healthcare S.A., Switzerland, a privately owned pharmaceutical group and its partner, MGI Pharma (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Capsules for oral ...
Zug (ots) - AmVac AG has a new executive officer on board - Dr. Wolfgang Schmidt agreed to join the company in early December to lead its operational business. Dr. Wolfgang Schmidt is a graduated chemist who began his career with Hoechst AG in Frankfurt/Main, Germany. After a variety of stints in pharmaceutical research, he directed the site-management Frankfurt department in the lead generation research segment. ...
Witterswil (ots) - Biolytix AG (www.biolytix.ch) signed a service provider agreement with Affymetrix UK Ltd (www.affymetrix.com) and offers genomic analysis services for the academic and industrial R&D community under conditions compliant with a stringent quality management system. Biolytix, one of the ...